 
UVA CENTER FOR DIABETES TECHNOLOGY  
 
   
 
 
Evaluation of The Postprandial Impact of 
Automated Priming Bolus for Full Closed Loop 
Insulin Delivery  
 
 
Protocol Chair 
Sue A. Brown, MD   
University of Virginia 
Center for Diabetes Technology  
  
NCT #05528770 
Version Number: v1.7 
06-Oct-2022  
CLINICAL PROTOCOL     
 
Rocket -BPS  06-Oct-2022  Page 2 of 56 
 
KEY ROLES  
 
Protocol Principal Investigator   
Name, degree  Sue Brown, MD  
Institution Name  University of Virginia Center for Diabetes Technology  
  
CLINICAL PROTOCOL     
 
Rocket -BPS  06-Oct-2022  Page 3 of 56 
 
PROTOCOL VERSION HISTORY  
Version 
Number  Author(s)  Approver  Effective Date  Revision Description  
1.0 Mark DeBoer ,  
Mary Oliveri  Sue Brown 29-Jul-2022  Original Protocol  
1.1 Mary Oliveri  Mark DeBoer  15-Aug-2022  FDA requested mods:  
• Figure 1 was updated  
• BPS transitions described 
(section 7.6) 
1.2 Mark DeBoer  Mark DeBoer  16-Aug-2022  FDA requested mods:  
• Inclusion & exclusion criteria 
(section 3.5 & 3.6) 
• Pilot study BPS corrections 
(section 6.3 & 6.4) 
• Exercise termination criteria 
(section 7.8) 
• Discharge criteria (section 
7.9) 
• Individual stopping criteria 
(section 11.10.1 ) 
1.3 Mary Oliveri  Sue Brown 23-Aug-2022  FDA requested mods:  
• Pilot study will complete  a 
minimum of 2 -3 participants 
(section  1.3, 3.2 & Chapter 6 ) 
• A H&P within 9 months of 
screening appointments may 
be used (section 3.4 & 3.7) 
• Further modified Exercise 
termination criteria (section 
7.8)  
• Discharge criteria (section 
6.6) 
1.4 Mary Oliveri  Sue Brown 12-Sep-2022  IRB Pre -Review mods (07 -Sep-
2022) :  
• Clarified enrollment numbers 
(section 3.2 & 13.2) 
• Edited inclusion criteria 
(section 3.5). 
• Edited Screening Process 
(section  3.4 &  3.7) 
• Deleted references to 
questionnaires (section 5.1, 
7.2, & 7.10) 
• Added 5 -minute low intensity 
warm up (section 7.7) 
• Clarified Covid testing 
(section 9.1.3) 
• Deleted Covid vaccination 
record (section 10.3) 
CLINICAL PROTOCOL     
 
Rocket -BPS  06-Oct-2022  Page 4 of 56 
 
• Edited pre -screening 
description  (section 3.7) 
1.5 Sue Brown Sue Brown 25-Sep-2022  IRB FB Review request:  
• SAP description ( Chapter 13).  
1.6 Mary Oliveri  Mary Oliveri  27-Sep-2022  IRB FB Review request:  
• Remove screening remote 
references  
1.7 Mary Oliveri  Mary Oliveri  06-Oct-2022  IRB FB Review request:  
• Clarified Part 11 
identification process  (section  
15.3.1 )  
 
  
CLINICAL PROTOCOL     
 
Rocket -BPS  06-Oct-2022  Page 5 of 56 
 
SITE PRINCIPAL INVESTIGATOR STATEMENT OF COMPLIANCE  
 
Protocol Title: Evaluation of The Postprandial Impact of Automated Priming Bolus for Full Closed 
Loop Insulin Delivery 
Protocol Version/Date: v1 .7  06- Oct-2022 
I have read the protocol specified above.  In my formal capacity as a Site Principal Investigator, 
my duties include ensuring the safety of the study participants enrolled under my supervision.  It 
is understood that all information pertaining to the study will be held strictly confidential and that 
this confidentiality requirement applies to all study staff at this site.  
This trial will be ca rried out in accordance with ICH E6 Good Clinical Practice (GCP) and as 
required by the following: United States (US) Code of Federal Regulations (CFR) applicable to 
clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 
CFR Part 812). 
As the Principal Investigator, I will assure that no deviation from, or changes to the protocol 
will take place without prior agreement from the sponsor and documented approval from the 
Institutional Review Board (IRB), or other approved Ethics Committee, except where necessary 
to eliminate an immediate hazard(s) to the trial participants.  
All key personnel (all individuals responsible for the design and conduct of this trial) have completed Human Participants Protection Training and Good Clinical Practice Training.  Further, 
I agree to ensure that all staff members involved in the conduct of this study are informed about 
their obligations in meeting the above commitments.  
 
Investigator’s Signature __________________________________Date: _ ____ / _____ / _____ 
Investigator’s Name: ________________________________ 
Site Name:  University of Virginia 
  
CLINICAL PROTOCOL     
 
Rocket -BPS  06-Oct-2022  Page 6 of 56 
 
LIST OF ABBREVIATIONS  
ABBREVIATION  DEFINITION  
ADRR  Average Daily Risk Range  
AP Artificial Pancreas  
BG Blood Glucose  
BT/BTLE  Bluetooth, Bluetooth low energy  
BPS Bolus Priming System  
CGM Continuous Glucose Monitoring  
CLC Closed -Loop Control  
CSII Continuous Subcutaneous Insulin Injection  
DKA Diabetic Ketoacidosis  
DSMB  Data Safety Monitoring Board  
FCL Fully Closed Loop 
FDA Food and Drug Administration  
GCP Good Clinical Practice  
HbA1c  Hemoglobin A1c  
HBGI  High Blood Glucose Index  
HIIT High -intensity interval training  
HCL  Hybrid Closed Loop  
IDE Investigational Device Exemption  
IOB Insulin-on -Board  
LBGI  Low Blood Glucose Index  
POC Point -of-Care 
QC Quality Control  
UI User Interface  
  
CLINICAL PROTOCOL     
 
Rocket -BPS  06-Oct-2022  Page 7 of 56 
 
PROTOCOL SUMMARY  
PARTICIPANT AREA  DESCRIPTION  
Title  Evaluation of The Postprandial Impact of Automated Priming Bolus for Full Closed Loop 
Insulin Delivery  
Investigational Device  UVA Model Predictive Control Artificial Pancreas (RocketAP) with and without use of the 
Bolus Priming System (BPS) 
Objectives  The purpose of this study is to show the sa fety and feasibility of a new fully automated AP 
controller with and without the Bolus Priming System  
Study Design  A randomized cross -over trial  assessing glycemic responses to a fully automated  AP system 
using two  approaches :  
1) using the Bolus Priming System (which detects shifts in glucose level to trigger a priming 
dose of insulin)  
2) without the Bolus Priming System  
We will also have structured meal and exercise challenges of the fully closed loop system.  
Number of Sites  One 
Endpoint  The primary outcome will be time in range 70 -180 mg/dL for a 24- hour period. 
Population  Key Inclusion Criteria  
• Age 18 and ≤65 years of age  
• Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one 
year  
• Currently u sing insulin for at least six months  
• Currently using insulin pump for at least three months  
Sample Size   • Pilot Study: complete a minimum of 2 -3 participant s  
• Main Study : complete up to 20  participants  
Treatment Groups  Randomized crossover:  Participants will be randomized to the order that they experience 
the use of the BPS in fully automated closed loop (FCL)  (for 24 hours each, with a 24 -hour 
washout in between): 1) with the BPS active, 2) without BPS.   
Participant  Duration  Pilot Study:  Participants will be admitted to a local hotel or rental house for up to 
approximately 24 hours and will have a dinner with the Rocket AP without the BPS  
Main Study: Participants will be admitted to a local hotel for approximately 96 hours.  
Protocol Overview/Synopsis  Main Study participants will be admitted to the hotel for a 4- night study, receiving the two 
sessions in random order: 1) FCL  with BPS activated , 2) FCL without the BPS , with a 24 -
hour washout period in between. During the admission, participa nts will receive structured 
meals and have blood glucose control followed to compare time in range 70-180 mg/dL between Controller sessions .  After the first 24 hour period on the first FCL approach (BPS 
vs. no BPS,)  that the participant has been randomized to, there will be a 24 hour challenge 
period before shifting to the other randomized approach; during this session participants will undergo further testing of the control algorithm, including meal challenges and a high-
intensity interval training bout.  
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 8 of 56 
 STUDY VISITS AND PROCEDURES SCHEDULE   
 
Screening  Study Equipment 
Training  Pre-Admission 
Check -In Study Admission  Post-Admission 
Check -In 
Location  Clinic  Clinic/ Remote  Phone/ Email/ 
Text  Hotel/Rental 
House  Phone/ Email/ 
Text  
Visit  1 2 3 4 5 
Informed Consent  X     
Eligibility Assessment  X     
Medical History  X     
HbA1c  X     
Pregnancy test (if applicable)  X X  X  
Physical Exam  X     
Vital Signs (height/weight)  X   X  
Electrocardiogram (ECG)  X     
Demographic Survey  X     
Randomization     X  
COVID -19 Testing    X   
CGM Use     X  
Survey  X     
Review diabetes management and AEs     X X 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 9 of 56 
 TABLE OF CONTENTS  1 
Chapter 1 Background  ..........................................................................................13  2 
1.1 Introduction ......................................................................................................................... 13  3 
1.2 Study Objective ................................................................................................................... 14  4 
1.3 Study Design ....................................................................................................................... 14  5 
1.4 Study Device Download ..................................................................................................... 16  6 
1.5 Study System Issues ............................................................................................................ 16  7 
Chapter 2 Study Devices  .......................................................................................18  8 
2.1 Insulin Pump ....................................................................................................................... 18  9 
2.2 Continuous Glucose Monitor .............................................................................................. 18  10 
2.3 Blood Glucose Meter and Strips ......................................................................................... 18  11 
2.4 Ketone Meter and Strips ..................................................................................................... 18  12 
2.5 Study Devices Accountability Procedures .......................................................................... 18  13 
Chapter 3 Study Screening  ...................................................................................19  14 
3.1 Clinical Sites  ....................................................................................................................... 19  15 
3.2 Participant Recruitment and Enrollment ............................................................................. 19  16 
3.3 Informed Consent and Authorization Procedures ............................................................... 19  17 
3.4 Screening Procedures .......................................................................................................... 19  18 
3.5 Participant Inclusion Criteria .............................................................................................. 19  19 
3.6 Participant Exclusion Criteria ............................................................................................. 20  20 
3.7 Visit 1: Screening Procedures ............................................................................................. 21  21 
3.8 Demographic Data Survey .................................................................................................. 23  22 
Chapter 4 Randomization  .....................................................................................25  23 
4.1 Pilot Study Participants ....................................................................................................... 25  24 
4.2 Main Study Participants ...................................................................................................... 25  25 
Chapter 5 Visit 2: Study Equipment Training  ....................................................26  26 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 10 of 56 
 5.1 CGM Training ..................................................................................................................... 26  27 
5.2 Activity Tracker .................................................................................................................. 26  28 
5.3 Study Insulin Pump ............................................................................................................. 27  29 
Chapter 6 P ilot Study  ............................................................................................28  30 
6.1 Qualifications and Role of the Staff.................................................................................... 28  31 
6.2 Visit 3: Pre-Admission Check- In Visit  ............................................................................... 28  32 
6.3 Visit 4: Admission Check- In .............................................................................................. 28  33 
6.4 Study Meals ........................................................................................................................ 29  34 
6.5 Admission Activities  ........................................................................................................... 29  35 
6.6 Admission Discharge .......................................................................................................... 29  36 
6.7 Visit 5: Post Admission Check- In Visit  .............................................................................. 30  37 
Chapter 7 Main Study  ...........................................................................................31  38 
7.1 Hotel Admission ................................................................................................................. 31  39 
7.2 Qualifications and Role of the Staff.................................................................................... 31  40 
7.3 Visit 3: Pre-Admission Check- In Visit  ............................................................................... 31  41 
7.4 Visit 4: Admission Check- In .............................................................................................. 31  42 
7.5 System Transitions .............................................................................................................. 32  43 
7.6 Study Meals ........................................................................................................................ 32  44 
7.7 Admission Activities  ........................................................................................................... 33  45 
7.8 Admission Discharge .......................................................................................................... 34  46 
7.9 Visit 5: Post Admission Check- In Visit  .............................................................................. 34  47 
7.10 Medical Monitor Review .................................................................................................. 34  48 
Chapter 8 Medical Monitor Review  .....................................................................35  49 
8.1 Medical Monitor Study Safety Data Review ...................................................................... 35  50 
8.2 Medical Monitor Main Study Safety Data Review ............................................................ 35  51 
Chapter 9 Testing Procedures  ..............................................................................36  52 
9.1 Laboratory / Point of Care Testing ..................................................................................... 36  53 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 11 of 56 
 Chapter 10 Risks Associat ed with Clinical Trial  ................................................37  54 
10.1 Potential Risks and Benefits of the Investigational Device .............................................. 37  55 
10.2 General Considerations ..................................................................................................... 40  56 
10.3 COVID- 19 Risk Mitigation Plan and Justification  ........................................................... 41  57 
Chapter 11 Adverse Events, Device Issues, and Stopping Rules .......................42  58 
11.1 Definitions......................................................................................................................... 42  59 
11.2 Reportable Events ............................................................................................................. 43  60 
11.3 Relationship of Adverse Event to Study Device............................................................... 44  61 
11.4 COVID-19 Transmission .................................................................................................. 44  62 
11.5 Intensity of Adverse Event................................................................................................ 45  63 
11.6 Coding of Adverse Events ................................................................................................ 45  64 
11.7 Outcome of Adverse Events ............................................................................................. 45  65 
11.8 Reportable Device Issues .................................................................................................. 46  66 
11.9 Timing of Event Reporting ............................................................................................... 46  67 
11.10 Stopping Criteria ............................................................................................................. 47  68 
11.11 Independent Safety Oversight ......................................................................................... 48  69 
11.12 Definition of a Data Breach ............................................................................................ 48  70 
Chapter 12 Miscellaneous Considerations  ..........................................................49  71 
12.1 Prohibited Medications, Treatments, and Procedures ....................................................... 49  72 
12.2 Participant Withdrawal ..................................................................................................... 49  73 
12.3 Confidentiality .................................................................................................................. 49  74 
Chapter 13 Statistical Consideration  ...................................................................50  75 
13.1 Design and Randomization ............................................................................................... 50  76 
13.2 Sample Size ....................................................................................................................... 51  77 
13.3 Outcome Measures............................................................................................................ 51  78 
13.4 Safety Analyses ................................................................................................................. 52  79 
13.5 Baseline Descriptive Statistics  .......................................................................................... 52  80 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 12 of 56 
 13.6 Device Issues .................................................................................................................... 52  81 
Chapter 14 Data Collection and Monitoring  .......................................................53  82 
14.1 Case Report Forms and Device Data ................................................................................ 53  83 
14.2 Study Records Retention................................................................................................... 53  84 
14.3 Protocol Deviations ........................................................................................................... 53  85 
Chapter 15 Ethics/Protection of Human Participants  .......................................54  86 
15.1 Ethics Standard ................................................................................................................. 54  87 
15.2 Institutional Review Boards .............................................................................................. 54  88 
15.3 Informed Consent Process ................................................................................................ 54  89 
Chapter 16 References  ...........................................................................................56  90 
 91 
  92 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 13 of 56 
 Chapter 1  Background 93 
 
 94 
A major impediment to maintaining blood glucose (BG) control in  Type 1 diabetes (T1D) is missed 95 
meal boluses, which has been associated with significantly higher HbA1c levels .1  While the 96 
advent of the artificial pancreas (AP) offers promise of safe reductions in HbA1c, our research 97 
group previously found that current  AP systems only partly compensates for missed prandial 98 
insulin .2 We thus designed a new system called RocketAP  to be fully automated, utilizing  a Bolus 99 
Priming System (BPS) that recognizes meal ingestion and delivers a quick priming dose of insulin 100 
prior to extreme blood sugar excursions. When used as a fully automated closed loop (FCL) system 101 
(without any meal announcements to the controller), this system improves time -in-range compared 102 
to a current commercially available system (Con trol-IQ). However, we have not previously 103 
determined whether the BPS provides improved blood sugar control over what the Rocket AP 104 
controller could without the BPS.  Indeed, when the BPS provides a bolus, it reduces the amount 105 
of insulin the controller can provide in response to high blood sugars —leaving open the possibility 106 
that the Rocket AP controller could provide a similar degree of blood sugar control after 107 
unannounced meals.  In addition, this system needs to be further tested under challenging 108 
conditi ons of exercise and food intake.  This is particularly true for the BPS, given the potential 109 
that the BPS could detect spurious changes in blood sugar and provide a priming dose of insulin 110 
in the absence of a meal.   111 
In the current study, the maximum amount of insulin that the BPS injects (which varies based on 112 
the system’s calculation of the probability that a meal has been ingested) is 6% of the person’s 113 
total daily insulin for any individual meal. This system is equipped with a novel hypoglycemia  114 
anti-rebound system , which constrains insulin infusion after  CGM /SMBG readings <70 mg/dL. 115 
The BPS system is also silenced at night (23:00 – 6:00h). 116 
In the current study, we are testing this Rocket AP system for BG levels using two approaches :  117 
A randomized cross -over trial where each participant will experience FCL for two 24- hour study 118 
periods in random order (referred to as FCL1 and FCL2) with : 119 
• The BPS functioning 120 
• The BPS inactivated  121 
During the washout period between FCL1 and FCL2, we will test the Rocket AP system in FCL  122 
with further challenges, both before and after the change in BP S treatment arm —i.e., not as a 123 
cross -over assessment but a comparison between participants randomized to start with  or without 124 
BPS.  These challenges will include:  125 
• A session of high- intensity interval training  (assessing the safety of the BPS when BG’s 126 
may spike during bursts of anaerobic activity) 127 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 14 of 56 
 • A high-carbohydrate, high- fat meal (assessing how the system  responds to prolonged 128 
carbohydrate absorption) 129 
• Ingestion of a bolus of simple sugar (assessing the safety of the BPS when the user’s 130 
blood sugar spikes from a relatively low amount of carbohydrate)    131 
Participants  will be admitted to a hotel and started o n the RocketAP for the purpose of comparing 132 
FCL use with and without BPS  as described above, all implemented on the DiAs platform ( MAF 133 
2109).  As an assessment of the efficacy of the system in maintaining BG control, participants will 134 
be followed for appro ximately 24 hours in the randomized phase (FCL1 vs. FCL2) and during the 135 
24-hour cross -over phase. Our primary outcome will be one of efficacy in assessing BG control  136 
(TIR 70 -180 mg/dL) between the two 24-hour FCL1/FCL2 periods.  137 
We hypothesize that  performances of  Rocket AP without BPS in FCL will provide similar glycemic 138 
control as  FCL with BPS.  We expect that this will constitute an important step toward having a 139 
fully automated  AP system  because it may remove the need for a BPS system that itself  could 140 
increase risk of episodes of hypoglycemia.  141 
 
 142 
The purpose of this study is to  test the performance of  the Rocket AP in FCL  both with and without 143 
the BPS, assessing efficacy and safety . We will target  completion of up to 20 adults in a 144 
randomized cross -over trial, comparing blood glucose time in range 70- 180 mg/dL for two 24- 145 
hour periods  and assessing TIR during an additional challenge period, which will be compared 146 
between those who started on BPS vs. those who did not.    147 
 
 148 
We will consent up to 30 participants,  ages ≥18.0 and ≤65 ye ars, with a goal to have up to 20 149 
participants complete the trial. The study will be performed overnight at a local hotel /rental  house 150 
(heretofore referred to as “hotel ”). Enrollment in the Pilot Study will proceed with the goal of 151 
completing a minimum of 2 -3 participants. This admission will be about 24 hours  at a hotel/rented 152 
house. Enrollment in the Main Study will proceed with th e goal of completing 20 participants.   153 
1.3.1 Study Hardware/Software 154 
The study itself will involve use of the DiAs prototyping platform (MAF 2109), connected to a 155 
Tandem t:AP research pump and a Dexcom G6 sensor, and implementing Rocket AP with and 156 
without BPS.  Upon arrival at the hotel, participants will be instructed in how to use the Tandem 157 
research pump as well as the UVa AP  system, including stopping the system.  158 
1.3.2 Timing of UVa Artificial Pancreas Use 159 
The participants will arrive to hotel  the evening before s tarting the experimental system to allow 160 
for a settling of blood glucose  in an unfamiliar environment. The next morning, participants will 161 
be connected to a Tandem research pump  connected to the UVa DiAs platform and their Dexcom 162 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 15 of 56 
 G6 Transmitter will be linked with DiAs. Participants will then be taught how to use DiAs in this 163 
configuration. The research pump will be programmed  with the individual ’s usual insulin 164 
parameters. Once started, the p articipants will have their blood sugar managed through this  system 165 
during the entirety of the time at hotel. 166 
1.3.3 Study Controller Ses sions 167 
Order and timing  of controller sessions : During the hotel stay, participants will have two separate 168 
24-hour periods during which they will receive FCL control with and without the BPS active .  169 
These will be separated by a 24 -hour challenge period which will involve further challenges.  The 170 
timing and potential order of these sessions is shown in Figure 1. 171 
 172 
Figure 1:  Timeline and randomized order of the Study Controller Sessions  173 
During these 24- hour periods participants will be followed for the experimental meals as part of 174 
the Study Controller Sessions to compare blood glucose control with and without the BP S (Figure 175 
1). The study meals and activities will be standardized between study sessions (see Figure 2).  176 

CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 16 of 56 
  177 
Figure 2:  Timeline of Study Controller Sessions and Study Meals  and activities .  There will be two identical 24- 178 
hour periods (FCL1 in green and FCL2 in orange), separated by a 24- hour challenge period (FCL1 in green -hatched) 179 
that will first involve the BPS activation assignment  the participant was randomized to  (the treatment approach used 180 
in FCL1)  and then involve the alternate assignment  (the treatment approach to be used in FCL2) , with the system 181 
switch at the end of the challenge day.  Arrows represent meals with Blue Arrows representing meals in which the 182 
participants are using their personal devices.  183 
The primary outcome will compare the percent time CGM is between 70 and 180 mg/dL during 184 
daytime  for F CL1 and FCL2 sessions with and without BPS .  During the time between arrival at 185 
the hotel and being started on the experimental system, participants will use their home diabetes 186 
management approach, including insulin dosing via normal carbohydrate announcement.  S tarting 187 
the first morning of the study (Day 2 of study), study staff who will be present will include nursing 188 
staff and technical staff ; a study physician will be available either on- site or nearby off -site at all 189 
times . Hyperglycemia and hypoglycemia treatment protocols will be followed per guidelines. We 190 
anticipate more significant cases of hyperglycemia during meals on the study system because of 191 
the lack of carbohydrate announcement; participants will be encouraged to drink large amounts of 192 
non-caloric beverages, particularly after these meals . UVa CDT study staff will monitor CGM 193 
output continuously and manage glucose control issues.  At the end of the hotel stay , the participant 194 
will return to their home insulin management.  195 
 
 196 
Before discharge from the hotel, all study devices will be turned in to study staff for device 197 
download, and the participants will return to their usual diabetes management . 198 
 
 199 
If the CGM signal becomes unavailable for more than 20 minutes consecutively, closed loop will 200 
not operate to automatically adjust insulin.  If the CGM is not connected, the system will revert to 201 
usual function of the pump and deliver insulin with the insulin dosing parameters programmed in 202 

CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 17 of 56 
 the system for that individual. Resumption of c losed-loop control will occur  automatically once 203 
CGM signal is available again.  204 
If the study system is unable to maintain pump connectivity, the pump will automatically revert to 205 
pre-programmed basal insulin delivery after 30  minutes without any need for instruction from the 206 
user.   207 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 18 of 56 
 Chapter 2  Study Devices  208 
 
 209 
The study system s will utilize  the Tandem t:AP  research pump  connected to the UVa DiAs system 210 
run on a dedicated external smart phone, running the R ocket AP control algorithm with  either the 211 
BPS system  active or not, with the order of these sessions determined randomly. 212 
 
 213 
The study CGM will include Dexcom G6 transmitter and sensors. The CGM sensor is viable for 214 
10 days. 215 
 
 216 
Blood glucose levels will be measured during the hotel admission with the use of a study 217 
glucometer. The CGM device will be calibrated, if needed, using the study glucometer and strips 218 
in accordance with the manufacturer’s labelling .  219 
 
 220 
Blood ketone levels will be measured during the hotel admission with the use of the Abbott 221 
Precision Xtra meters and strips in accordance with the manufacturer’s labelling . The blood 222 
glucose meter component of the Precision Xtra Device will not be used.   223 
 
 224 
Device serial numbers will be recorded , and use of equipment will be tracked.  225 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 19 of 56 
 Chapter 3  Study Screening   226 
 
 227 
The study will be performed at the University of Virginia, with screening procedures taking place 228 
either virtually, at the Clinical Research Unit, or at local hotel.  229 
 
 230 
Pilot Study:  Enrollment goal in the Pilot Study will be to complete  a minimum of 2 -3 participant s. 231 
Up to 6 participants may sig n consent forms.  232 
Main Study:  Enrollment in the s tudy will proceed with the goal of completing up to 20 233 
participants .  Participants will initially be randomized for the order of using FCL with or without 234 
BPS.  Up to 30 participants may sign the consent form.  235 
 
 236 
Before consent has been obtained, participants will be asked inclusion/exclusion criteria questions 237 
during pre-screening  to determine study eligibility. Before completing any procedures or 238 
collecting any data that are not part of usual  care, written inform ed consent, when applicable) will 239 
be obtained. Potential eligibility may be assessed as part of a routine-care examination.   240 
A participant is considered enrolled when the informed consent form has been signed by the 241 
participant and the study team. 242 
Consenting procedures and documentation is defined in section 15.3.  243 
 
 244 
After informed consent has been signed, a potential participant will be evaluated for study 245 
eligibility through the elicitation of a medical history, performance of a physical examination 246 
by licensed  personnel, an ECG, and pregnancy testing (if applicable) to screen for exclusionary 247 
medical conditions.   248 
A physical exam documented in the prior 9 months can suffice for the physical exam  but will not 249 
serve as an exclusionary criterion  if not available . Participants may self -report height ,  weight , 250 
blood pressure, temperature, and heart rate . Individuals who do not initially meet study eligibility 251 
requirements may be rescreened at a later date per investigator discretion.  252 
 
 253 
The participants must meet all of the following inclusion criteria in order to be eligible to 254 
participate in the study. 255 
1. Age ≥18.0 a nd ≤65 years old  at time of consent  256 
2. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year  257 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 20 of 56 
 3. Currently using insulin for at least six months 258 
4. Currently using insulin pump for at least three months  259 
5. Using insulin parameters such as carbohydrate ratio and correction factors consistently on 260 
their pump in order to dose insulin for meals or corrections  261 
6. Current regular exercise (e.g. wal k, bike, jog) and be able to participate in a high intensity 262 
interval training activity.  263 
7. Access  to internet and willingness to upload data during the study as needed  264 
8. For females, not currently known to be pregnant or breastfeeding  265 
9. If female and sexually active, must agree to use a form of contraception to prevent p regnancy 266 
while a participant in the study.  A negative serum or urine pregnancy test will be required for 267 
all females of child bearing potential. Participants who become pregnant will be discontinued 268 
from the study. Also, participants who during the study develop and express the  intention to 269 
become pregnant within the timespan of the study will be discontinued. 270 
10. Willingness to suspend use of any personal CGM for the duration of the clinical trial once the 271 
study CGM is in use 272 
11. Willingness to use the UVa closed -loop system throughout study admission  273 
12. Willingness to use personal lispro (Humalog) or aspart (Novolog)  during the study admission.  274 
13. Willingness not to start any new non-insulin glucose- lowering agent during the course of the 275 
trial (including metformin/biguanides, GLP -1 receptor agonists, pramlintide, DPP -4 276 
inhibitors, sulfonylureas and naturaceuticals) 277 
14. Willingness to eat at least 1  g/kg of carbohydrate per day during the hotel admission  278 
15. Willingness to reschedule if placed on oral steroids  279 
16. An understanding and willingness to follow the protocol and signed informed consent  280 
17. Willingness to follow COVID -19 protocols in place at the time of study.  281 
 
 282 
The participant must not have any exclusion criteria in order to be eligible to participate in the 283 
study.  284 
1. History of diabe tic ketoacidosis (DKA) in the 6  months prior to enrollment 285 
2. Severe hypoglycemia resulting in seizure or  loss of consciousness in the 12 months prior to 286 
enrollment 287 
3. Pregnancy or intent to become pregnant during the trial 288 
4. Currently being treated for a seizure disorder 289 
5. Planned surgery during study duration. 290 
6. Treatment with meglitinides/sulfonylureas at the time of hotel study. 291 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 21 of 56 
 7. Use of metformin/biguanides, GLP -1 agonists, pramlintide, DPP -4 inhibitors, SGLT -2 292 
inhibitors, or naturaceuticals with a change in dose in the past month.  293 
8. Coronary artery disease or heart failure, unless written clearance is received from a   294 
cardiologist or personal health care provider allowing clearance for high- intensity interval 295 
training and documentation of a negative stress test within the year 296 
9. History of cardiac arrhythmia (except for benign premature atrial contractions and benign 297 
premature ventricular contractions which are permitted or previous ablation of arrhythmia 298 
without recurrence which may be permitted)  299 
10. Clinically significant electrocardiogram (ECG) at time of Screening, as interpreted by the 300 
study medical physician. 301 
11. A known medical condition that in the judgment of the investigator might interfere with the 302 
completion of the protocol such as the following examples: 303 
a. Inpatient psychiatric treatment in the past 6 months  304 
b. Presence of a known adrenal disorder 305 
c. Abnormal liver function test results (Transaminase >2 times the upper limit of 306 
normal); testing required for subjects taking medications known to affect liver 307 
function or with diseases known to affect liver function 308 
d. Uncontrolled thyroid disease 309 
e. Musculoskeletal or other condition that limits participation in exercise portion of 310 
study 311 
12. A known medical condition that in the judgment of the investigator might interfere with the 312 
completion of the protocol. 313 
13. Positive Covid-19 test result   314 
 
 315 
The participant will be evaluated for study inclusion and exclusion eligibility  after the informed 316 
consent form has been signed by the participant and the study team.  317 
Individuals who do not initially meet study eligibility requirements may be rescreened at a later 318 
date per investigator discretion. 319 
Screening procedures will last appr oximately 1 -2 hours. The visit may occur in- person or  by 320 
telecommunication. The following procedures may be performed/data collected/eligibility criteria 321 
checked and documented:  322 
1. Inclusion and Exclusion criteria assessed  323 
2. Demographics, including: 324 
a. Date o f birth 325 
b. Gender  326 
c. Race  327 
d. Ethnicity  328 
3. Medical History , including diabetes history  329 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 22 of 56 
 a. Duration of disease (number of years) 330 
b. Current insulin pump model 331 
c. History of CGM use 332 
d. Current treatment  333 
e. Severe hypoglycemia history 334 
f. Severe hyperglycemia history 335 
g. History of seizures  336 
h. Loss of consciousness 337 
4. Basal rates  338 
5. Carbohydrate ratios  339 
6. Insulin sensitivity factors  340 
7. Target glucose 341 
8. Average daily insulin 342 
9. Surgical history 343 
10. Allergies  344 
11. Concomitant medications  345 
12. Electrocardiogram (ECG)   346 
13. Physical Examination – Aa historical history and physical report within 9 months of 347 
screening appointments may be used but is not required for eligibility. If vitals are not 348 
available, may include self -reported values .  349 
a. Weight  (may be self -reported)  350 
b. Height (may be self -reported)  351 
c. Blood pressure 352 
d. Temperature  353 
e. Heart Rate  354 
14. Screening Labs  355 
a. Hemoglobin A1c point of care  356 
b. Urine or serum pregnancy test for all women of childbearing potential (this test can 357 
be done remotely with results sent to the study team) 358 
If needed based on medical history, investigators may include baseline chemistry panel, liver 359 
function tests, hematocrit , and thyroid stimulating hormone (lab results within one year of 360 
screening appointment may be used). 361 
Up to 6 months of historical data from the participant’s personal insulin pump, glucometer, or 362 
continuous glucose monitor may be downloaded or recorded. Data will be obtained from the 363 
participant’s personal insulin pump and CGM. This data may be obtained through the commercial 364 
applications (e.g. t:connect and Dexcom G6).  365 
If participants are on -site, the participant’s glucometer may be uploaded to ensure that the 366 
participant can successfully upload the equipment.  367 
Any labs required may be obtained at a local laboratory (e.g. LabCorp) convenient to the 368 
participant.  369 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 23 of 56 
 This study is not meant to find out if the participant has any other disease or problem. The study 370 
leaders will alert the participant if any of the research results are important to his/her health during 371 
the study. The participant may have a copy of the screening tests to discuss with the personal 372 
physician. When the blood tests are completed, any blood left over will be thrown away. It will 373 
not be stored for any future testing. 374 
For potential subjects who live out of state and or a significant distance from UVA to facilitate the 375 
consent process, e -consent will be used. Note: For potential participants  who are not able to use 376 
DocuSign, email, fax, or mail  will be an option for receipt of the signed consent. The consenting 377 
process will involve discussing the study at length in a phone call/HIPAA compliant 378 
telecommunication method with the interested potential participant.  The potential participant will 379 
be asked permission to review inclusion/exclusion criteria to assess if they are eligible to 380 
participate in the study.  If permission is granted, the study team will review the pre- screening  381 
questionnaire which contains the inclusion/exclusion criteria.  If eligible, the study team member 382 
will provide a copy of the informed consent form (i.e. in person, email, or mail) to the potential 383 
participant for their review. Potential p articipants may also elect to choose to review the informed 384 
consent form prior to discussing pre -screening  questions.  385 
The potential participant will be given an opportunity to ask the study team questions or may speak 386 
directly with the study physician. After ample time to make an informed decision, the potential 387 
participant may sign the consent form at home and provide it to the study team (e.g. in person, 388 
electronically, email, fax, or mail).  The potential participant’s understanding of the information, 389 
presented in the process of consent will be assessed by asking open- ended questions, may occur 390 
during the phone call or at the screening appointment. Once consent is obtained, study procedures 391 
may begin (e.g. LabCorp).  392 
The study physician or physician designee will have the discretion to repeat screening tests. The 393 
repeat screening tests may be conducted locally (e.g. LabCorp). The participant may request a 394 
copy of any of the results from the screening evaluation to review with their primary care provider.  395 
If an exclusionary condition is identified, the study participant will be excluded from participation 396 
with follow u p and referral to their primary care physician as needed.  397 
If the study participant is pregnant, the study physician will discuss the results of the blood test 398 
with the participant and the participant will be asked to seek confirmation of the test and the 399 
appropriate medical care.  400 
Participants may be re- screened at a later date if their clinical situation changes as determined by 401 
the study physician. 402 
 
 403 
Research in diabetes technology has revealed significant disparities in minoritized population’s 404 
representation in clinical trials and access to devices that improve diabetes outcomes.  C ollection 405 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 24 of 56 
 of detailed demographic data regarding participants in technology trials has become essential.  This 406 
includes data on race/ethnicity, income levels and insurance status, as well as education and other 407 
variables that describe the study population.  408 
The Demo graphic Data Survey will be electronically administered once eligibility has been met.  409 
a. Gender  410 
b. Race  411 
c. Ethnicity  412 
d. Marital status  413 
e. Level of education  414 
f. Employment status  415 
g. Household income 416 
h. Health i nsurance status  417 
i. Monthly insulin costs   418 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 25 of 56 
 Chapter 4  Randomization  419 
Participants  will receive the t wo different experimental conditions (FCL  with and without BPS ) in 420 
random order as described below. 421 
 
 422 
Pilot participants will not be randomized and will use the Rocket AP system with and with out BPS . 423 
 
 424 
Once eligibility is met and screening procedures are completed, the participant may continue to 425 
randomizati on. Screening failures and study dropout participants may be replaced. Randomization 426 
will occur via permuted blocks of 4.    427 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 26 of 56 
 Chapter 5  Visit 2: Study Equipment Training  428 
Equipment training may begin at the hotel after UVa AP system has been pu t in place.   The purpose 429 
of this training is to introduce the study insulin pump and study CGM to the participant.  430 
The participant’s insulin parameters will be programmed into their study insulin pump and 431 
confirmed by two research staff. Subjects will then switch to the study insulin pump. The 432 
participant’s personal pump and infusion site will be removed. 433 
The participant will have the insulin pump and sensor on them at all times.  434 
 
 435 
A study CGM will be provided to all participants at the training session. The participant s will be 436 
provided with CGM equipment and instructed to use the study CGM on a daily basis. If the 437 
participant has  prior use of the CGM , re-training will be specific to the individual.  The study team 438 
may elect to have less frequent CGM users watch the Dexcom online training videos 439 
(https://www.dexcom.com/training -videos) to assist in the training session .  Study staff t raining 440 
may include review of study CGM in real -time to make management decisions and how to review 441 
the data after an upload for retrospecti ve review. Study staff will specifically identify how alarms 442 
are set using the app and the frequency that these alarms will repeat.  443 
The participants personal CGM will be discontinued. The participants will be observed placing the 444 
sensor and will learn/revi ew how to access the CGM trace via the DiAs phone or the Tandem 445 
research pump, as needed. The participants will be asked to perform fingerstick blood glucose 446 
measurements (if needed) in accordance with the labelling  of the study CGM device.  447 
An electronic copy of the CGM user’s guide will be provided for the participants to read . The 448 
study team will be sure that the participants will leave the training session knowing how to properly 449 
use the CGM. The study team will be available for any questions. 450 
Participants will have the option of using their personal smartphone or receive a study smartphone 451 
to use in order to collect the data from the devices. If the participant elects to use a personal device, 452 
the Dexcom app will be downloaded to their phone in order to monitor the participant’s CGM 453 
values and alerts in real -time may be used.  454 
 
 455 
All participants may be asked to wear an activity tracker (e.g. Fitbit) during the entire study (home 456 
and hotel admissions) to record information about movement and heart rate though not an endpoint 457 
in this study. 458 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 27 of 56 
 
 
 459 
The study team will be responsible for monitoring and managing the study insulin pump during 460 
the hotel admission s. The participants may be provided a quick overview  on its funct ionality to 461 
understand the equipment. 462 
5.3.1 Study Insulin Pump Topics   463 
The study team will assist the participant in study pump infusion site initiation and will start the 464 
participant on the study pump. The study pump will be programmed with the participant’s us ual 465 
basal rates and pump parameters. The participant’s personal pump will be removed. The 466 
investigator may elect to use an existing personal pump infusion site at their discretion at the start 467 
of the study. 468 
The participant will be instructed on charging the pump, navigation through menus, bolus 469 
procedures including stopping a bolus, etc. 470 
5.3.2 Other Issues  471 
The participant will be instructed to  notify study staff if they experience any issues with the study 472 
devices during the hotel admission. Staff will be present in the event that if insulin is delivered by 473 
any means other than the study pump (e.g. injection of subcutaneous insulin via syringe in the 474 
event of infusion site failure). If insulin is delivered by any means other than the study pump, the 475 
study team wi ll be instructed to turn off closed -loop mode for approximately four hours. 476 
The participant will also be asked to alert  the study clinical staff for technical issues with the 477 
Tandem research pump and/or the DiAs system, including use of the study pump and study CGM 478 
(open loop mode) during periods of component disconnections or technical difficulties.  479 
A glucagon emergency kit will be available at the hotel once the investigational system is in place.  480 
Glycemic Treatment Guidelines will be available for staff use during the study admissions. 481 
5.3.3 Optimization of Insulin Pump Settings  482 
Data- driven optimization of pump settings can occur any time prior to the hotel admission, 483 
particularly if the participant contacts the study physician due to concerns about their pump 484 
settings due to recurring hypo- or hyperglycemia. No pump settings changes can occur during 485 
closed loop testing.  486 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 28 of 56 
 Chapter 6   Pilot Study   487 
In order to optimize the flow of the study visits during the Main Study, we will perform a Pilot 488 
Study at a local hotel or rent al house. The duration of the pilot admission will be approximately 489 
24 hours with the intent of testing the logistics of our stud y procedures.  The goal will be to 490 
complete  2-3 participants. Pilot study participants are eligible to enroll in the Main Study.  491 
Participants and staff will adhere to the Covid- 19 Mitigation Plan as outlined in Section  10.3   492 
 
 493 
For the pilot study, t here will be at least two study staff present at all times at the study site, at least 494 
one of whom will be clinical staff (e.g. nurse, physician, nurse practitioner, physician assistant). 495 
There will be a physician available either on -site or off- site within a n approximate  20-minute drive 496 
at all times.  In addition, one of the study medical physicians and one senior engineer will be on 497 
call during the entire admission. Glucagon for the emergency treatment of hypoglycemia will be 498 
available on -site. 499 
 
 500 
Pilot participants will be contacted by the study team approximately 24- 48 hours prior to the hotel 501 
admission to verify the following information: 502 
• Inquire about any changes to the participant’s medical history  503 
• Study equipment (e.g. CGM  and activity tracker) initiation has occurred  504 
• Determine pump profile(s) the participant us es on certain days  505 
• New CGM sensor has been placed approximately 24 -72 hours prior to admission for proper 506 
warm -up 507 
• Verify with the participant that the goal CGM reading on  day 2 is less than 200 mg/dL; 508 
this may require contact with the study physician prior today 2 of the hotel study.  509 
• Should any concerns regarding medical history, pump information, or unforeseen issues 510 
arise, the admission will be cancelled for that participant at the discretion  of the investigator  511 
 
 512 
For the pilot study, one to three  p articipant s will be assessed at a time.  The participant will arrive 513 
at the hotel on the first day of the admission.  The study team will perform vital signs and inquire 514 
about any changes to the participant’s medical history.  Any changes to medical history will be 515 
communicated to the medical physician to ensure continued eligibility and participation.   516 
A urine pregnancy test will be collected  if relevant . The test must be  negative for the participant 517 
to continue with the study.  518 
The subject’s CGM reading, and ketone concentration will be recorded. In the event that the 519 
participant’s CGM reading is not between 80- 250 mg/dL or ketone concentration is ≥ 0.6 mmol/L 520 
prior to ini tiation  of the UVa AP system , the study physician may recommend  additional insulin 521 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 29 of 56 
 dosing according to the participants’ usual doses . Study physician may elect to cancel participant’s 522 
participation in the hotel admission if concerned about their medical safety.  This participant will 523 
not be replaced.  524 
The participant’s home insulin pump will be discontinued, and the study Tandem research  insulin 525 
pump will be initiated  using the RocketAP system with BPS activated .  The study team will ensure 526 
the proper function of the CGM, insulin pump, and activity tracker. T he goal will be to initiate 527 
Closed -Loop Control by approximately lunch time, running the Rocket AP system  on the DiAs 528 
platform .  529 
The CGM used in the study is FDA -approved for the non- adjunctive measurement of blood 530 
glucose (i.e. the CGM reading can be used for insulin dosing decisions). The CGM readings will 531 
be the primary source of blood glucose values .  There are no protocol fingerstick blood glucose 532 
measurements other than at times of CGM calibration (if necessary) and if directed by the study 533 
team. Fingers tick blood glucose measurements may be taken whenever participants experience 534 
symptoms, if the CGM glucose is suspected to be erroneous, or any time the participant would like 535 
to be reassured.  536 
 
 537 
Participants will eat a structured dinner at approximately 6 -7 pm during the admission. The 538 
participant will not announce carbohydrate ingestion, allowing testing of the RocketAP controller 539 
with BPS following dinner . Breakfast in the morning will be with the BPS system engaged. 540 
Throughout the Pilot study, the participant will remain in closed loop mode.  541 
 
 542 
In the afternoon after admission, participants will participate in a supervised bout of high- intensity 543 
interval training (see details in Section 7.8). D uring this time, the system will have BPS activated. 544 
Apart from the programmed exercise portions, participants will be free to engage in low- intensity 545 
activity ( i.e. walking) during the admission . Participants will enjoy quiet activities in the evening. 546 
 
 547 
Discharge will be at approximately noon. D ischarge criteria is CGM value 80 -300 mg/dL with 548 
stable trend and ketones <=0.6 mmol/L. I f the CGM values are above 300 mg/dL and ketone values 549 
are >0.6 mmol/L, the study team will check the insulin pump infusion site and correction insulin 550 
will be administered per study physician judgement via the subject’s insulin pump.   A qualified 551 
clinical study team member (e.g. MD, NP, PA, CDE) will assess and discuss the transition back to 552 
usual care with t he study participant.    553 
Participants will be asked to continue monitoring ketone levels for 24- 48 hours after the hotel 554 
admission  if ketones were >0.6 mmol/L at time of discharge. Urine ketone supplies may be 555 
provided for this testing.   556 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 30 of 56 
 
 
 557 
Approximately 24- 48 hours after the hotel admission, the study team will contact the participant 558 
via phone/email/text/text to assess adverse events, adverse device effects, and device issues . 559 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 31 of 56 
 Chapter 7   Main Study  560 
 
 561 
Main Study participants will participate in hotel admission . Each admission will be up to 562 
approximately 96 hours in duration.  563 
Participants and staff will adhere to the Covid-19 Mitigation Plan as outlined in Section 10.3.   564 
 
 565 
There will be at least two  study staff present at all times at the study site, at least one of whom will 566 
be clinical staff (e.g. nurse, physician, nurse practitioner, physician assistant). There will be a 567 
physician at the hotel  or nearby on call  during the study at all times.  In addit ion, at least  one senior 568 
engineer will be on call during the entire admission. P articipants will be remotely monitored by at 569 
least one study team  member  using a web- based remote monitoring system that has been 570 
previously established for DiAs .  The web -based remote monitoring system will display real- time 571 
insulin delivery, CGM and other system information to allow for patient safety monitoring.    In 572 
addition, study team members will be trained in all protocol and glycemic treatment guideline 573 
procedures. The closed -loop system will be managed by the participant with study- staff 574 
supervision, particularly at the time of insulin boluses .  Glucagon for the emergency treatment of 575 
hypoglycemia will be available on- site. 576 
 
 577 
Partici pants will be contacted by the study team approximately 24- 48 hours prior to each  hotel 578 
admission  if most recent contact with the study participant exceeds 10 days. T he study team will 579 
verify the following information: 580 
• Inquire about any changes to the participant’s medical history  581 
• Study equipment (e.g. CGM and activity tracker) initiation has occurred  582 
• Determine pump profile(s) the participant uses on certain days 583 
• New CGM sensor has been placed approximately 24- 72 hours prior to admission for proper 584 
warm -up 585 
• Verify with the subject that the goal CGM reading at time of arrival is less than 200 mg/dL; 586 
this may require contact with the study physician prior to arrival on the day of the study 587 
visit  588 
• Should any concerns regarding medical history, pump information, or unforeseen issues 589 
arise, the admission will be cancelled for that participant at the discretion of the investigator  590 
 
 591 
Participants will arrive at the hotel on the first day of the admission.  As described in section 10.3, 592 
all participants will receive a  test for COVID -19 after arriving for the study .  The study team will 593 
perform vital signs and inquire about any changes to the participant’s medical history.  Any 594 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 32 of 56 
 changes to medical history will be communicated to the medical physician to ensure continued 595 
eligibility and participation.   596 
A urine pregnancy test will be collected  for female participants of childbearing age . The test must 597 
be negative for the participant to continue with the study.  598 
The subject’s CGM reading, and ketone concentration will be recorded. In the event that the 599 
participant’s CGM reading is not between 80- 250 mg/dL or ketone concentration is ≥0.6 mmol/L 600 
prior to initiation of the UVa artificial pancreas system, the study physician may recommend  601 
additional insulin dosing according to the participants’ usual doses. Study physician may elect to 602 
cancel participant’s participation in the hotel admission if concerned about their medical safety.  603 
This participant will not be replaced.  604 
The participant’s home insulin pump will be discontinued, and the  study insulin pump will be 605 
initiated.  The study team will ensure the proper function of the CGM, insulin pump, and activity 606 
tracker.   607 
The CGM used in the study is FDA -approved for the non- adjunctive measurement of blood 608 
glucose (i.e. the CGM reading can be used for insulin dosing decisions). The CGM readings will 609 
be the primary source of blood glucose values.  There are no protocol fingerstick blood glucose 610 
measurements other than at times of CGM calibration (if necessary) and if directed by the study 611 
team.  Fingerstick blood glucose measurements may be taken whenever participants experience 612 
symptoms, if the CGM glucose is suspected to be erroneous, or any time the participant would like 613 
to be reassured. Glycemic Treatment Guidelines to be used during the hotel admission are defined 614 
in a separate document.  615 
 
 616 
Participants will be informed beforehand and at the time of the transfer from one BPS state to 617 
another.  Participants will be told what this transition means with respect to insulin do sing.  The 618 
transfer from one treatment to another will proceed as follows: 619 
• The system is stopped 620 
• DiAs is plugged into a laptop and ‘parameters.xml’ file (with the corresponding BPS 621 
condition) will be replaced  622 
• DiAs is restarted  623 
• CGM is recovered and pump connections is checked 624 
• DiAs is transitioned to Closed Loop Control mode  625 
 
 626 
Participants will eat structured study meals during the admission, with the same amount of 627 
carbohydrate, protein and fat for meals (breakfast, lunch, dinner) on the days for FCL1 and FCL2).  628 
During the 24- hour challenge period, there will be additional meal challenges that will only be 629 
performed on that day.  This includes a high carbohydrate high fat meal at dinner (such as pizza) 630 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 33 of 56 
 and a n early breakfast that consists prima rily of fast -acting carbs (e.g.. juice).  In all cases the 631 
carbohydrate content of the meal will not be announced during the study once the AP system has 632 
been placed .  Snacks with carbohydrates will not be allowed unless for the treatment of low blood 633 
sugars. Non- carbohydrates snacks may be allowed throughout the protocol per investigator 634 
discretion, but the intention is not to have non- carbohydrate snacks.  Blood glucose levels will be 635 
followed via continuous glucose monitor and glucose values will be managed by the AP system 636 
as usual.  637 
 
 638 
During the study, we will challenge the participants with exercise sessions that will be supervised 639 
by study staff.  During FCL1 and FCL2, participants will do a mild to moderate walking or similar 640 
exercise at approximately 4pm on each of those study days. 641 
During the challenge phase (the 24- hour period between the FCL1 and FCL2), participants will 642 
undergo supervised session of high- intensity interval training (HIIT). The HIIT workout will 643 
consist of a 5-minute  low intensity warmup period, a workout of about 1 minute of vigorous 644 
exercise followed by approximately 2 minutes of light intensity exercise or rest. This 3- minute set 645 
of intervals may be repeated up to 6 times or until volitional exhaustion, followed by approximately 646 
5 minutes of light intensity cooldown and stretching. The goal of this will be to assess the safety 647 
of the AP system in HIIT, given that HIIT has been observed to result in an increase in BG levels, 648 
which could theoretically lead to activation of the BPS —dosing insulin.  The AP system will be 649 
monitored for BPS activation during this workout.  If the BPS is activated, participants will 650 
continue to be monitored for BG excursions, including receiving treatment for hypoglycemia if 651 
this occurs (as described in the Glycemic Treatment Guidelines) .   652 
Exercise challenges will be terminated early with subjective symptoms such as shortness of breath, 653 
chest pain, dizziness, palpitations,  or any such concerning symptoms reported by participants. 654 
Participants will stop their participation in the exercise portion of the study if reporting any 655 
concerning symptoms. Study physicians (or physician’s assistants) will assess the participants for 656 
their need for additional care outside the study. If symptoms resolve entirely and there is no 657 
additional requirement for care outside the study, participants will stop participation in the exercise 658 
portion of the study and will not repeat that portion of the study. Participants however may then 659 
continue with the remainder of the study per investigator discretion.  660 
Participants will also be free to engage in low -intensity activity ( i.e. walking) during the hotel 661 
admission  but will be asked to have this match between 24-hour study periods as best as possible . 662 
Partici pants may leave the hotel to be outside, provided they are accompanied by a study staff 663 
member and follow COVID precautions in place at the time of study,  as described in Section .3. 664 
Participants will enjoy quiet activities in the evening.  665 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 34 of 56 
 
 
 666 
Discharge will be at approximately  1 pm . Discharge criteria is CGM value 80 -300 mg/dL with 667 
stable trend and ketones <=0.6 mmol/L. If the CGM values are above 300 mg/dL and ketone values 668 
are >0.6 mmol/L, the study team will check the insulin pump infusion site and correction insulin 669 
will be administered per study physician judgement via the subject’s insulin pump. A qualified 670 
clinical study team member (e.g. MD,  NP, PA, CDE) will assess and discuss the transition back to 671 
usual care with the study participant.    672 
Participants will be asked to continue monitoring ketone levels for 24- 48 hours after the hotel 673 
admission  if ketones were >0.6 mmol/L prior to discharge. Urine ketone supplies may be provided 674 
for this testing.  675 
All study equipment will be returned at the time of study end. Per investigator discretion, a 676 
participant may wear home the study CGM device in use and will be requested to return the study 677 
transmitter.  678 
 
 679 
Approximately 24- 48 hours after the hotel admission, the study team will contact the participant 680 
via phone/email/text to assess adverse events, adverse device effects, and device issues .  681 
 
 682 
At the conclusion of the Main Study, the medical monitor will review the data as referenced in 683 
section 8.3.    684 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 35 of 56 
 Chapter 8   Medical Monitor Review  685 
 
 686 
The Medical Monitor  will be provided all adverse event data for review  to assess safety .  The 687 
Medical Monitor will review data related to individual stopping criteria as detailed in the study 688 
protocol.   689 
 
 690 
A Medical Monitor will review compiled safety data at the conclusion of the trial. In addition, the 691 
Medical Monitor  will review all DKA and severe hypoglycemia irrespective of relatedness to study 692 
device use, and all seri ous events (including UADEs) related to study device use at the time of 693 
occurrence. The Medical Monitor  also will be informed of any ADEs not meeting criteria for a 694 
UADE if the Study PI requests the Medical Monitor review.  The Medical Monitor  can request 695 
modifications to the study protocol or suspension or stoppage of the study if deemed necessary 696 
based on the totality of safety data available.   697 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 36 of 56 
 Chapter 9   Testing Procedures  698 
 
 699 
9.1.1 HbA1c  700 
A blood sample will be obtained at screening to obtain a baseline hemoglobin A1c level. A blood 701 
test obtained within 2 weeks prior to enrollment may be used. 702 
HbA1c level may be measured by study team using the DCA2000, a comparable point of care 703 
device, at  time of screening   704 
Labs may be obtained at a local laboratory (e.g. LabCorp) convenient to the participant. 705 
9.1.2 Pregnancy Test  706 
A serum or urine pregnancy test will be required for women of childbearing potential at in person 707 
visit and admission.  Test must be negative to participate in the study.  708 
9.1.3  Covid-19 Testing 709 
All participants  and study staff (e.g. on- site research coordinators, technicians, nurses , and 710 
physicians) will be tested with a COVID -19 test within the first 24 hours of the hotel admission or 711 
up to 72 hours in advance of being on -site for the Pilot and Main Study.  Individuals with Covid- 712 
19 positive tests will be excluded from the study.   713 
9.1.4 Demographic Data Survey 714 
The Demographic Data Survey will be asked after study eligibility has been met.   715 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 37 of 56 
 Chapter 10  Risks Associated with Clinical Trial 716 
 
 717 
Risks and Benefits are detailed below. Loss of confidentiality is a potential  risk; however, data are 718 
handled to minimize this risk . Hypoglycemia, hyperglycemia and ketone formation are always a 719 
risk in participants with type 1 diabetes and participants will be monitored for these symptoms.  720 
10.1.1 Venipuncture Risks  721 
A hollow needle/plast ic tube may  be placed in the arm for taking blood samples  (e.g. external 722 
HbA1c measurements for inclusion criteria) . Blood draws can cause some common reactions like 723 
pain, bruising, or redness at the sampling site.  Less common reactions include bleeding from the 724 
sampling site, formation of a small blood clot or swelling of the vein and surrounding tissues, and 725 
fainting. 726 
10.1.2 Fingerstick Risks  727 
About 1 drop of blood will be removed by fingerstick for measuring blood sugars and sometimes 728 
HbA1c or other tests. This  is a standard method used to obtain blood for routine hospital laboratory 729 
tests.  Pain is common at the time of lancing.  In about 1 in 10 cases, a small amount of bleeding 730 
under the skin will produce a bruise. A small scar may persist for several weeks . The risk of local 731 
infection is less than 1 in 1000. This should not be a significant contributor to risks in this study 732 
as finger sticks are part of the usual care for people with diabetes. 733 
10.1.3 Subcutaneous Catheter Risks (CGM)  734 
Participants using the CGM will be at low risk for developing a local skin infection at the site of 735 
the sensor needle placement . If a catheter is left under the skin for more than 24 hours it is possible 736 
to get an infection where it goes into the skin, with swelling, redness and pain.  T here may be 737 
bleeding where the catheter is put in and bleeding under the skin causes a bruise (1 in 10 risk). 738 
Study staff should verbally alert the participant that on rare occasions, the CGM may break and 739 
leave a small portion of the sensor under the skin that may cause redness, swelling, or pain at the 740 
insertion site . The participant should be further instructed to notify the study coordinator 741 
immediately if this occurs.  742 
10.1.4 Risks of Hypoglycemia  743 
As with any person having type 1 diabetes and using insulin, there is always a risk of having a low 744 
blood sugar (hypoglycemia) . The frequency of hypoglycemia should be no more and possibly less 745 
than it would be as part of daily living. Symptoms of hypoglycemia can include sweating, 746 
jitteriness, and not feeling well.  Just as at home, there is the possibility of fainting or seizures 747 
(convulsions) and that for a few days the participant may not be as aware of symptoms of 748 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 38 of 56 
 hypoglycemia.  A CGM functioning poorly and significantly over -reading glucose values could 749 
lead to inappropriate insulin delivery. 750 
10.1.5 Risks of Hyperglycemia  751 
Hyperglycemia is likely because of the study design including unannounced carbohydrate 752 
ingestion.  Also, hyperglycemia and ketonemia could occur if insulin delivery is attenuated or 753 
suspended for an extended period or if the pump or infusion set is not working properly.  A CGM 754 
functioning poorly and significantly under -reading glucose values could lead to inappropriate 755 
suspension of insulin delivery. 756 
10.1.6 Risks of Device Reuse  757 
Participant will be informed that FDA or relevant national authorities have approved the insulin 758 
pump, CGM, glucometer and ketone meter for single use and that by using them among multiple 759 
patients, bloodborne pathogens (i.e. Hepatitis B) may be spread through the use of mult iple users.  760 
The study CGM system is labelled  for single use only. The sensor (the component of the system 761 
that enters the skin) will be single use only. The transmitter and receiver may be reused during the 762 
study after cleaning the device using a hospital -approved cleaning procedure. The transmitter is 763 
attached to the sensor but does not enter the skin and the receiver, if used, is a handheld device.  764 
The study insulin pumps are label led for single -patient use. During the study, this device may be 765 
reused af ter cleaning adhering to a hospital -approved cleaning procedure. All infusion set 766 
equipment will be single patient use only (infusion set insertion kits, tubing, cartridges etc.).   767 
The study blood glucose meter and blood ketone meter are labe lled for single -patient use. 768 
During the study, these devices may be reused after cleaning adhering to a hospital -approved 769 
cleaning procedure.   770 
10.1.7 Device Cleaning Instructions  771 
CGM cleaning instructions are provided in the Dexcom G4 P latinum (Professional) Cleaning and 772 
Disinfection manual (current edition) and a similar approach will be applied for the G6 version 773 
used in this study. The transmitter should be cleaned with Clorox Healthcare® Bleach Germicidal 774 
Cleaner or any disinfectant product in a spray bottle containing a bleach solution of 6500 parts per 775 
million with the EPA registration number 56392- 7.  The transmitter will be submerged in this 776 
solution and then placed on an absorbent wipe or clean surface.  Two sprays will be dispensed 777 
from the Clorox cleaner onto each side of the transmitter. A nylon brush will be used to scrub the 778 
transmitter on all sides for 30 seconds.  The transmitter will be placed in the Clorox Cleaner 779 
solution for one minute. Transmitter is then rinsed under flowing tap water for ten seconds. The 780 
transmitter will then be disinfected using a disinfectant product with EPA registration number 781 
56392-7 using similar procedures as the cleaning process.   782 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 39 of 56 
 Per the pump manufacturer, the insulin pump will be cleaned with a damp lint -free cloth. Use of 783 
house hold or industrial cleaners, solvents, bleach, scouring pads, chemicals, or sharp instruments 784 
are prohibited. The pump should never be submerged in water. If needed, use only a very mild 785 
detergent, such as a bit of liquid soap with warm water. A soft to wel will be used to dry the pump.  786 
The glucometer is cleaned and disinfected with two separate Super Sani -Cloths (EPA number 787 
9480-4). The entire surface will be cleaned, making sure the surface stays wet for 2 minutes. This 788 
step is repeated with a clean cl oth for disinfecting the device.  789 
The Precision Xtra User’s Guide suggests that healthcare professionals use 10% bleach, 70% 790 
alcohol or 10% ammonia to clean the device.  791 
Equipment that touches intact skin will be cleaned with ethyl or isopropyl alcohol (70- 90%), 792 
quaternary ammonium germicidal detergent (i.e. Cavicide, EPA number 46781) or household 793 
bleach. The contact time on the surface depends on the method used to clean the equipment. 794 
Cavicide requires three minutes on the surface of the equipment. Clorox Germicidal Bleach Wipes 795 
require two minutes on the equipment. The surface should remain wet (i.e. slightly damp) with the 796 
disinfectant to be considered effective though not wet enough to leave drops of liquid.  797 
In the event a manufacturer updates cleanin g procedures for their device, the study team will 798 
adhere to the most current recommendations.  799 
There is the risk of blood sampling collection and contamination from sampling techniques. Hand 800 
washing with either soap & water or waterless hand sanitizer wil l be used prior to caring for the 801 
study subject. Gloves will be worn during blood sample collection and processing. Medical 802 
personnel will continue to practice hygiene for the subject’s protection (i.e. hand washing, 803 
changing gloves frequently, disposing needles properly). Gloves will be removed, and hands 804 
washed  or sanitized  prior to leaving and upon return to the subject’s room. Soiled linen will be 805 
changed to minimize the transfer of pathogenic organisms. 806 
10.1.8 Risk of Exercise  807 
There is a risk of  musculoskelet al symptoms or injury from participating in an exercise regimen. 808 
There are cardiovascular or cerebrovascular risks (including but not limited to dizziness, 809 
lightheaded, syncope, arrhythmia or ischemia) associated with participating in an exercise 810 
regimen. The intention of the eligibility criteria will be to minimize these risks.  811 
10.1.9 Hb1Ac Risk  812 
An NGSP Point of Care analyzer (i.e. DCA Vantage Analyzer) will be utilized at the research site 813 
to obtain the subject’s HbA1c level. 814 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 40 of 56 
 10.1.10 Other Risks  815 
Some participants may develop skin irritation or allergic reactions to the adhesives used to secure 816 
the CGM, or to secure the insulin infusion sets for the continuous subcutaneous insulin infusion.  817 
If these reactions occur, different adhesives or “under -taping” (such as with IV 3000, Tegaderm, 818 
etc.) will be tried, sites will be rotated frequently, and a mild topical steroid cream or other 819 
medication may be required. 820 
Whenever the skin is broken there is the possibility of an infection.  The CGM and pump infusion 821 
sites are insert ed under the skin.  It is possible that any part that is inserted under the skin may 822 
cause an infection.  These occur very infrequently, but, if an infection was to occur, oral and/or 823 
topical antibiotics can be used.  The risk of skin problems could be greater if you use a sensor for 824 
longer than it is supposed to be used.  Therefore, participants will be carefully instructed about 825 
proper use of the sensor. 826 
Data downloaded from the CGM, pump, glucometer, and ketone meter will be collected for the 827 
study as me asures of diabetes self -management behaviours. Some people may  be uncomfortable 828 
with the researchers' having such detailed information about their daily diabetes habits. 829 
10.1.11 Known Potential Benefits  830 
It is expected that this protocol will yield increased knowledge about using an automated closed- 831 
loop system with anticipatory action to control glucose levels. The individual participant may not 832 
benefit from study participation. 833 
10.1.12 Risk Assessment  834 
Based on the facts that (1) adults with diabetes experi ence mild hypoglycemia and hyperglycemia 835 
frequently as a consequence of the disease and its management, (2) the study intervention involves 836 
periodic automated insulin dosing that may increase the likelihood of hypoglycemia, and periodic 837 
automated attenuati on of insulin delivery that may increase the likelihood of hyperglycemia, (3) 838 
mitigations are in place, and have been tested in prior studies using the investigational device 839 
system in the home setting, that limit the likelihood of excessive insulin dosing  or prolonged 840 
withdrawal of insulin, and (4) rapid reversal of hypoglycemia and hyperglycemia can be achieved.. 841 
In addition, it is the belief of the investigators that this study also presents prospect of direct benefit 842 
to the participants and general bene fit to others with diabetes.  843 
 
 844 
The study is being conducted in compliance with the policies described in the study policies 845 
document, with the ethical principles that have their origin in the Declaration of Helsinki, with the 846 
protocol described herein, and with the standards of Good Clinical Practice (GCP). 847 
Whenever possible, data will be directly collected in electronic case report forms, which will be 848 
considered the source data.  849 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 41 of 56 
 The protocol is considered a significant risk device study, due to the fact that the closed -loop 850 
system is experimental.  Therefore, an investigational device exemption (IDE) from the U.S. Food 851 
and Drug Administration (FDA) is required to conduct the study. 852 
 
 853 
The study team will follow local guidelines that are in effect at the time of the study admission.  854 
10.3.1        Participants and Study Personnel  855 
We will follow a combination of approaches to increase our likelihood of having a COVID -free 856 
environment:    857 
• We will follow CDC and local guidelines in effect at the time of the study.  858 
• All participants and study  staff (research coordinators, technicians, nurses , and physicians ) 859 
will be tested with an FDA authorized COVID -19 test with the first 24 hours of  study 860 
start or up to approximately 72 hours before their participation in the study hotel .  861 
Those with positive tests will be excluded from the study.   862 
• Any participants with positive test will be  discharged from the study.  Hotel rooms of these 863 
participants will be restricted from future use . We will limit any personal interaction 864 
between study personnel and these individuals.  We will follow local guidelines in effect 865 
at the time of study to guide interactions .   866 
10.3.2  Environment  867 
The study team will adhere to current hotel guidelines.   868 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 42 of 56 
 Chapter 11  Adverse Events, Device Issues, and Stopping Rules  869 
 
 870 
11.1.1 Adverse Events (AE)  871 
Any untoward medical occurrence in a study participant, irrespective of the relationship between 872 
the adverse event and the device(s) under investigation ( section 11.2) for reportable adverse events 873 
for this protocol). 874 
Positiv e pregnancy test will be not considered adver se event .  875 
11.1.2 Serious  Adverse Event (SAE)  876 
 Any untoward medical occurrence that: 877 
• Results in death. 878 
• Is life -threatening; (a non- life-threatening event which, had it been more severe, might 879 
have become life- threateni ng, is not necessarily considered a serious adverse event). 880 
• Requires inpatient hospitalization or prolongation of existing hospitalization. 881 
• Results in persistent or significant disability/incapacity or substantial disruption of the 882 
ability to conduct norma l life functions (life threatening). 883 
• Is a congenital anomaly or birth defect. 884 
• Is considered a significant medical event by the investigator based on medical judgment 885 
(e.g., may jeopardize the participant or may require medical/surgical intervention to 886 
prevent one of the outcomes listed above). 887 
11.1.3 Unanticipated Adverse Device Effect (UADE)  888 
Any serious adverse effect on health or safety or any life-threatening problem or death caused by, 889 
or associated with, a device, if that effect, problem, or death was not previously identified in nature, 890 
severity, or degree of incidence in the investigational plan or application (including a 891 
supplementary plan or application), or any other unanticipated serious problem associated with a 892 
device that relates to the rights, sa fety, or welfare of participants (21 CFR 812.3(s)). 893 
11.1.4 Adverse Device Effect (ADE)  894 
Any untoward medical occurrence in a study participant which the device may have caused or to 895 
which the device may have contributed. 896 
11.1.5 Device Complaints and Malfunctions  897 
A device complication or complaint is something that happens to a device or related to device 898 
performance, whereas an adverse event happens to a participant . A device complaint may occur 899 
independently from an AE, or along with an AE . An AE may occur without a devi ce complaint or 900 
there may be an AE related to a device complaint.  A device malfunction is any failure of a device 901 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 43 of 56 
 to meet its performance specifications or otherwise perform as intended.  Performance 902 
specifications include all claims made in the labelling  for the device.  The intended performance 903 
of a device refers to the intended use for which the device is labelled  or marketed. (21 CFR 803.3).   904 
 
 905 
For this protocol, a reportable adverse event includes any untoward medical occurrence that meets 906 
one of the following criteria: 907 
• A serious adverse event  as defined in section 11.2  908 
• An Adverse Device Effect as defined in section 11.1.4, unless excluded from reporting in 909 
section 11.7 910 
• An Adverse Event as defined in section 11.1.1 occurring in association with a study 911 
procedure 912 
• An AE as defined in section 11.1.1 which leads to discontinuation of a study device for 2 913 
or more hours 914 
• Hypoglycemia meeting the definition of severe hypoglycemia as defined in section 11.2.1  915 
• Diabetic ketoacidosis (DKA) as defined in section 11.2.2 or in the absence of DKA, a 916 
hyperglycemic or ketosis event meeting the criteria defined below 917 
Hypoglycemia and hyperglycemia not meeting the criteria below will not be recorded as adverse 918 
events unless associated with an Adverse Device Effect . Skin reactions from sensor placement are 919 
only reportable if severe and/or required treatment. 920 
11.2.1 Hypoglycemia Event 921 
Hypoglycemia not associated with an Adverse Device Effect is only reportable as an adve rse event 922 
when the following definition for severe hypoglycemia is met:   923 
• The event required assistance of another person due to altered consciousness, and required 924 
another person to actively administer carbohydrate, glucagon, or other resuscitative action s 925 
• Impaired cognitively to the point that he/she was unable to treat himself/herself, was unable 926 
to verbalize his/ her needs, was incoherent, disoriented, and/or combative, or experienced 927 
seizure or coma. These episodes may be associated with sufficient neu roglycope nia to 928 
induce seizure or coma  929 
• If plasma glucose measurements are not available during such an event, neurological 930 
recovery attributable to the restoration of plasma glucose to normal is considered sufficient 931 
evidence that the event was induced by a low plasma glucose concentration 932 
11.2.2 Hyperglycemia Events/Diabetes Ketoacidosis  933 
Hyperglycemia not associated with an Adverse Device Effect is only reportable as an adverse 934 
event when one of the following four criteria is met:  935 
• The event involved DKA, as defined by the Diabetes Control and Complications Trial 936 
(DCCT) and described below  evaluation or treatment was obtained at a health care provider 937 
facility for an acute event involving hyperglycemia or ketosis 938 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 44 of 56 
 • Blood ketone level ≥1.5 mmol/L and communication oc curred with a health care provider 939 
at the time of the event  940 
• Blood ketone level ≥3.0 mmol/L, even if there was no communication with a health care 941 
provider 942 
Hyperglycemic events are classified as DKA if the following are present:  943 
• Symptoms such as polyuria, polydipsia, nausea, or vomiting  944 
• Serum ketones ≥1.5 mmol/L or large/moderate urine ketones  945 
• Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate <15 946 
• Treatment provided in a health care facility  947 
All reportable Adverse Events—whether volunteered by the participant, discovered by study 948 
personnel during questioning, or detected through physical examination, laboratory test, or other 949 
means —will be reported on an adverse event form online.  Each adverse event form is reviewe d 950 
by the Medical Monitor to verify the coding and the reporting that is required. 951 
 
 952 
The study investigator will assess the relationship of any adverse event to be related or unrelated 953 
by determining if there is a reasonable possibility that the adverse event may have been caused by 954 
the study device. 955 
To ensure consistency of adverse event causality assessments, investigators should apply the 956 
following general guideline when determining whether an adverse event is related:  957 
• There is a plausible temporal relationship between the onset of the adverse event and the 958 
study intervention, and the adverse event cannot be readily explained by the participant’s 959 
clinical state, intercurrent illness, or concomitant therapies; an d/or the adverse event 960 
follows a known pattern of response to the study intervention; and/or the adverse event 961 
abates or resolves upon discontinuation of the study intervention or dose reduction and, if 962 
applicable, reappears upon rechallenge.  963 
• Evidence exists that the adverse event has an etiology other than the study intervention 964 
(e.g., pre-existing  medical condition, underlying disease, intercurrent illness, or 965 
concomitant medication); and/or the adverse event has no plausible temporal relationship 966 
to study intervention. 967 
 
 968 
While we are taking steps to prevent transmission of COVID -19 during this study, there is a 969 
possibility that participants, based either on exposure before the hotel admission or during the stay, 970 
are infect ed with COVID -19.  Any appearance of significant COVID -19 symptoms in participants 971 
will be cause for repeat COVID -19 testing an d possible quarantine  until test results are returned.  972 
If this  Covid-19 test is positive, the participant will be discharged fro m the study.  973 
In the event of a COVID -19 positive test in a participant , the study team will follow up with the 974 
participant via phone until conclusion of treatment  for the COVID -19 related sy mptoms . All 975 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 45 of 56 
 participants will be asked to follow up via phone with the study team in the event of a positive test 976 
within 14 days after discharge from the hotel.  977 
 
 978 
The intensity of an adverse event will be rated on a three -point scale: (1) mild, (2) moderate, or (3) 979 
severe. It is emphasized that the term severe is a measure of intensity: thus, a severe adverse event 980 
is not necessarily serious . For example, itching for several days may be rated as severe, but may 981 
not be clinically serious. 982 
• MILD: Usually transient, requires no specia l treatment, and does not interfere with the 983 
participant’s daily activities.  984 
• MODERATE: Usually causes a low level of inconvenience or concern to the participant 985 
and may interfere with daily activities but is usually ameliorated by simple therapeutic 986 
measures.  987 
• SEVERE: Interrupts a participant’s usual daily activities and generally requires systemic 988 
drug therapy or other treatment. 989 
 
 990 
Adverse events will be coded per the UVA IRB website instructions (i.e. mild, moderate, severe).   991 
The Medical Monitor  will review the investigator’s assessment of causality and may agree or 992 
disagree.  Both the investigators  and Medical Monitor ’s assessments will be recorded.  The 993 
Medical Monitor will have the final say in determining the causality. 994 
Adverse events that continue after the participant’s discontinuation or completion of the study will 995 
be followed until their medical outcome is determined or until no further change in the condition 996 
is expected.  997 
 
 998 
The outcome of each reportable adverse event will be classified by the investigator as follows: 999 
• RECOVERED/RESOLVED – The participant recovered from the AE/SAE without 1000 
sequelae.  Record the AE/SAE stop date. 1001 
• RECOVERED/RESOLVED WITH SEQUELAE – The event persisted and had stabilized 1002 
without change in the event anticipated.  Record the AE/SAE stop date. 1003 
• FATAL – A fatal outcome is defined as the SAE that resulted in death. Only the event that 1004 
was the cause of death should be reported as fatal.  AEs/SAEs that were ongoing at the 1005 
time of de ath; however, were not the cause of death, will be recorded as “resolved” at the 1006 
time of death.  1007 
• NOT RECOVERED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is defined 1008 
as the event was ongoing with an undetermined outcome. 1009 
• An ongoing outcome will require follow- up by the site in order to determine the final 1010 
outcome of the AE/SAE. 1011 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 46 of 56 
 • The outcome of an ongoing event at the time of death that was not the cause of death, will 1012 
be updated and recorded as “resolved” with the date of death recorded as the stop date.  1013 
• UNKNO WN – An unknown outcome is defined as an inability to access the participant or 1014 
the participant’s records to determine the outcome (for example, a participant that was lost 1015 
to follow-up). 1016 
All clinically significant abnormalities of clinical laboratory measurements or adverse events 1017 
occurring during the study and continuing at study termination should be followed by the 1018 
participant’s physician and evaluated with additional tests (if necessary) until diagnosis of the 1019 
underlying cause, or resolution . Follow-up information should be recorded on source documents. 1020 
If any reported adverse events are present when a participant completes the study, or if a participant 1021 
is withdrawn from the study due to an adverse event, the participant will be contacte d for re - 1022 
evaluation within 2 weeks.  If the adverse event has not resolved, additional follow -up will be 1023 
performed as appropriate.  Every effort should be made by the Investigator or delegate to contact 1024 
the participant until the adverse event has resolved or stabilized.  1025 
 
 1026 
All UADEs, ADEs, device complaints, and device malfunctions will be reported irrespective of 1027 
whether an adverse event occurred, except in the following circumstances.  1028 
The following device issues are anticipated and will not be reported but will reported as an Adverse 1029 
Event if the criteria for AE reporting described above are met:  1030 
• Component disconnections 1031 
• CGM sensors lasting fewer than the number of days expected per CGM labelling  1032 
• CGM tape adherence issues  1033 
• Pump infusion set occlusion not leading to ketosis 1034 
• Battery lifespan deficiency due to inadequate charging or extensive wireless 1035 
communication  1036 
• Intermittent device component disconnections/communication failures not leading to 1037 
system replacement  1038 
• Device issues clearly ad dressed in the user guide manual that do not require additional 1039 
troubleshooting 1040 
• Skin reactions from CGM sensor placement or pump infusion set placement that do not 1041 
meet criteria for AE reporting  1042 
 
 1043 
• UADEs must be reported within 10 working days to the FDA  after the sponsor first receives 1044 
notice of the adverse effect.  1045 
• Other reportable adverse events, device malfunctions (with or without an adverse event) 1046 
and device complaints should be reported promptly, but there is no formal required 1047 
reporting period. 1048 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 47 of 56 
 • The IDE Sponsor will investigate the UADE and if indicated, report the results of the 1049 
investigation to the IRBs, FDA, and DSMB  within 10 working days of the study team  1050 
becoming aware of the UADE per 21CFR 812.46(b) (2).  1051 
• The Medical Monit or will determine if the UADE presents an unreasonable risk to 1052 
participants. If so, the DSMB  must ensure that all investigations, or parts of investigations 1053 
presenting that risk, are terminated as soon as possible but no later than 5 working days 1054 
after the Medical Monitor  makes this determination and no later than 15 working days after 1055 
first receipt notice of the UADE.  1056 
• In the case of a device system component malfunction (e.g. pump, CGM, control 1057 
algorithm), information will be forwarded to the responsible manufacturer by the study 1058 
personnel. 1059 
 
 1060 
11.10.1 Participant Discontinuation  1061 
Rules for discontinuing study de vice use are described below.  1062 
• The investigator believes it is unsafe for the participant to continue the intervention.  This 1063 
could be due to the development of a new medical condition or worsening of an existing 1064 
condition; or participant behaviour contrary  to the indications for use of the device that 1065 
imposes on the participant’s safety 1066 
• The participant requests that the treatment be stopped  1067 
• The participant tests positive for COVID -19 (during study testing or otherwise within 14 1068 
days of study start) or subsequently develops symptoms for COVID-19 and tests positive. 1069 
• Diagnosis of DKA.  Any severe hypoglycemia event meeting the definition  in section 1070 
11.2.1 of the protocol. 1071 
11.10.2 Suspending/Stopping Overall Study  1072 
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or severe 1073 
hyperglycemia event (as defined in section 11.2.2), use of the study device system will be 1074 
suspended while the problem is diagnosed. 1075 
In the even t that two distinct episodes of DKA  or two distinct severe hypoglycemia events as 1076 
defined in section 11.2  occur , the overall study would be suspended while the underlying 1077 
conditions are determined.   1078 
In addition, study activities could be similarly suspended if the manufacturer of any constituent 1079 
study device requires stoppage of device use for safety reasons (e.g. product recall).  The affected 1080 
study activities may resume if the underlying problem can be corrected by a protocol or system 1081 
modification that will not invalidate the results obtained p rior to suspension. The study Medical 1082 
Monitor will review all adverse events and adverse device events that are reported during the study 1083 
and will review compiled safety data at periodic intervals . The Medical Monitor  may request 1084 
suspension of study activities or stoppage of the study if deemed necessary based on the totality 1085 
of safety data available.  1086 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 48 of 56 
 
 
 1087 
A Medical Monitor  will review all DKA and severe hypoglycemia irrespective of relatedness to 1088 
study device use, and all serious events (including UADEs) related to study device use at the time 1089 
of occurrence. The Medical Monitor  can request modifications to the study protocol or suspension 1090 
or outright stoppage of the study if deemed necessary based on the totality of safety data avai lable. 1091 
Details regarding Medical Monitor review will be documented in a separate Medical Monitor  1092 
document.   1093 
 
 1094 
A data breach is defined in the HITECH Act (43 USC 17932) as an unauthorized acquisition, 1095 
access, or use of protected health information (PHI) that compromises the security or privacy of 1096 
such information.   1097 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 49 of 56 
 Chapter 12  Miscellaneous Considerations  1098 
 
 1099 
Participants using glulisine at the time of enrollment will be asked to contact their personal 1100 
physician to change their prescribed personal insulin to lispro or aspart  for the duration of the trial.  1101 
The study devices (study insulin pump, study CGM) must be removed before Magnetic Resonance 1102 
Imaging (MRI), Computed Tomography (CT) or diather my treatment. Participants may continue 1103 
in the trial after temporarily discontinuing use if requiring one of the treatments above. 1104 
 
 1105 
Participation in the study is voluntary. P articipant may withdraw at any time.  For  participants who 1106 
do withdraw from the study, the study team will determine if their data will be used in analysis.  1107 
 
 1108 
For security and confidentiality purposes, subjects will be assigned an identifier that will be used 1109 
instead of their name.  Protected health information gathered for this study may be shared with the 1110 
third -party collaborators.  De -identified subject information may also be provided to collaborators 1111 
involved in the study after the appropriate research agreement has been executed.  1112 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 50 of 56 
 Chapter 13  Statistical Consideration 1113 
 
 1114 
The main  study is itself a n early exploratory study to assess glycemic responses of a fully closed- 1115 
loop system (Rocket AP).  This information is detailed in Table 1.  1116 
Randomization will occur via selection from the above list using permuted blocks in groups of 4.   1117 
13.1.1 Planned Analysis 1118 
Our primary objective is to assess the impact of priming bolus on post prandial FCL control therefore we 1119 
will test the following statistical hypotheses  1120 
 1121 
a. Null Hypothesis:  There is no difference in the means of time spent in the 70 -180mg/dL range during 1122 
daytime between FCL with and without prandial priming bolu s (BPS at 6% and 0% of TDI respectively)  1123 
 1124 
b. Alternative Hypothesis:  There is a difference in the means of time spent in the 70 -180mg/dL range during 1125 
daytime between FCL with and without prandial priming bolus (BPS at 6% and 0% of TDI respectively)  1126 
 1127 
To do so we will use repeated measure ANOVA models to predict daytime time in range with the BPS 1128 
status a fixed effect and baseline HbA1c and gender as covariates.  1129 
 1130 
Secondary outcomes:  1131 
All secondary outcomes will be similarly analyzed. If an outcomes distribution is not suited for mixed 1132 
model analysis (e.g. profound skewness, or large atom at boundary) we will perform paired Wilcoxon 1133 
signed rank test (and loose the capacity to use covariate) to test difference in the median instead of the 1134 
mean; this is expected for time below 70mg/dL, number of hypoglycemia, and possibly time above 1135 
250mg/dL.  1136 
 1137 
We do not plan to correct for multiple comparisons.  1138 
 1139 
We do not expect substantial missing values in this highly supervised study, but if more than 3 subjects 1140 
have one or more missing admissions, we will consider switching from RANOVA to mixed model repeated 1141 
measures.  1142 
 1143 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 51 of 56 
 
 
 1144 
As a early exploratory Study, the goal will be to complete up to 20 participants  in the main study 1145 
to provide data from a variety of individuals.  This number was chosen out of feasibility and not 1146 
from a formal power calculation.  (The Pilot Study  for this proposal will assess ease of system  and 1147 
will be completed in a minimum of 2 -3 individuals prior to the beginning of the Main Study.)  With 1148 
N=20 and our randomized crossover design (allowing for paired comparison), we can hope to detect a 1149 
minimum effect size of 0.66 at a power of 80%. Based of prior FCL study, the standard deviation of daytime 1150 
TIR is approximately 12%, leading to a detec table difference in daytime TIR of 8%.  1151 
 
 1152 
13.3.1 Primary Efficacy Endpoint  1153 
The study design allows for multiple comparisons of blood glucose control during the study meals 1154 
and exercise  sessions, with for the primary comparison of interest being bet ween the RocketAP 1155 
with and without BPS. Our primary endpoint is CGM time -in-range 70 -180 mg/dL for the daytime 1156 
period 6 a m – 12 am when on each treatment modality (BPS vs. no BPS) .  1157 
13.3.2 Secondary Outcomes 1158 
Each admission is separated in to windows of analysis: 1159 
• The entirety of the admission (24h: 4pm to 4pm) 1160 
• The 4 hours following each of the meals. 1161 
• The overnight period (12 am to 6 am) 1162 
For each of these periods we will compute the following outcomes: 1163 
• Number of hypoglycemia events defined as at least two consecutive CGM values 1164 
<70mg/dL or a hypoglycemia treatment (two events separated by less than 30 minutes are 1165 
counted as one). 1166 
• Percent CGM time < 70 mg/dL  1167 
• Percent CGM time between 80 -140mg/dL 1168 
• Percent CGM time between 70 -180mg/dL 1169 
• Percent CGM time  >180 mg/dL  1170 
• Percent CGM time > 250 mg/dL  1171 
• Units of insulin injected  1172 
• Area under the curve when accounting for starting BG  1173 
• Low Blood Glucose Index 1174 
• High Blood Glucose Index 1175 
• CGM coefficient of variation  1176 
• Mean CGM  1177 
 1178 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 52 of 56 
 13.3.3  CGM  data treatment  1179 
• Saturated CGM values “High” and “Low” will be replaced by 401mg/dL and 39mg/dL 1180 
respectively.  1181 
• Any CGM gaps shorter than 1 hour will be interpolated  1182 
• CGM data during recorded occlusion event will be removed from analysis as follow: 1183 
any measurement less than  2h before or after the time of record will be removed. 1184 
• CGM data following a pump/DiAs communication interruption >1h by less than 2h 1185 
will be removed  1186 
13.3.4  Outcome computation conditions  1187 
Outcomes will only be computed if at least 80% of the analysis window CGM m easurements (after data 1188 
treatment) are available  1189 
 
 1190 
We will assess for the system’s functionality, including the ability of the system to run its code 1191 
without error (delivering insulin safely, as planned), as well as its ability to avoid low BG <70 1192 
mg/dL. 1193 
 
 1194 
Baseline demographic and clinical characteristics of the cohort of all randomized participants will 1195 
be summarized in a table using summary statistics appropriate to the distribution of each variable. 1196 
Descriptive statistics will be displayed overall and by treatment group.  1197 
Will include: 1198 
• Age 1199 
• HbA1c  1200 
• Gender  1201 
• Race/ethnicity  1202 
• CGM use before enrollment 1203 
• AID use before enrollment 1204 
• Diabetes duration  1205 
• BMI  1206 
• Total Daily Insulin  1207 
 
 1208 
The following tabulations and analyses will be performed during time on the UVa AP systems to 1209 
assess device issues:  1210 
• Device malfunctions requiring study team contact and other reported device issues 1211 
• % time CGM data available  1212 
• % time with closed loop control  1213 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 53 of 56 
 Chapter 14   Data Collection and Monitoring 1214 
 
 1215 
The study data are collected through a combination of case report forms (electronic and paper) and 1216 
electronic device data files obtained from the software and individual hardware components . These 1217 
electronic device files and electronic CRFs are considered the primary source documentation.  1218 
When data are directly collected in electronic case report forms, this will be considered the source 1219 
data.  Records will be maintained in accordance with ICH E6 and institutional regulatory 1220 
requirements for the protection of confidentiality of participants. 1221 
 
 1222 
Study documents should be retained for a minimum of 2 years after the last approval of a marketing 1223 
application in an ICH region and until there are no pending or contemplated marketing applications 1224 
in an ICH region or until at least 2 years have elapsed since the formal discontinuation of clinical 1225 
development of the investigational product.  These documents should be retained for a longer 1226 
period, however, if required by local regulations . No records will be destroyed without the written 1227 
consent of the sponsor, if applicable . It is the responsibility of the sponsor to inform the investigator 1228 
when these documents no longer need to be retained. 1229 
 
 1230 
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practices 1231 
(GCP), or procedure requirements.  The noncompliance may be either on the part of the participant, 1232 
the investigator, or the study site staff . As a result of deviations, corrective actions may be 1233 
developed by the site and implemented as appropriate.  Major deviations will be reported to the 1234 
IRB-HSR within 7 calendar days of when the study team becomes aware of the event.  1235 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 54 of 56 
 Chapter 15   Ethics/Protection of Human Participants  1236 
 
 1237 
The investigator will ensure that this study is conducted in full conformity with Regulations for 1238 
the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 1239 
CFR Part 5 6, and/or the ICH E6. 1240 
 
 1241 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 1242 
be submitted to the IRB for review and approval.  Approval of both the protocol and the consent 1243 
form must be  obtained before any participant is enrolled.  Any amendment to the protocol will 1244 
require review and approval by the IRB before the changes are implemented to the study.  All 1245 
changes to the consent form will be IRB approved; a determination will be made regarding whether 1246 
previously consented participants need to be re- consented.  1247 
 
 1248 
15.3.1 Consent Procedures and Documentation  1249 
Informed consent is a process that is initiated prior to an individual’s agreement to participate in 1250 
the study and continues throughout the individual’s study participation.  Extensive discussion of 1251 
risks and possible benefits of participation will be provided.  Consent forms will be IRB approved 1252 
and the participant will be asked to read and review the document.  The investigator or their 1253 
delegate will explain the research study to the participant  and answer any questions that may arise.  1254 
All participants will receive a verbal explanation in terms suited to their comprehension of the 1255 
purposes, procedures, and potential risks of the study and of their rights as research participants.  1256 
Participant  will have the opportunity to carefully review the written consent form and ask questions 1257 
prior to signing. 1258 
The consenting process will involve discussing the study at length in a phone call/HIPAA 1259 
compliant telecommunication method for consenting that is not face to face. The participant will 1260 
sign the informed consent document prior to any procedures being done specifically for the study. 1261 
The consent form may be signed electronically with the use of the Part 11  compliant version of 1262 
DocuSign for both in- person and telecommunication  screening visits . The study team will follow 1263 
the FDA part 11 compliant process of  verification of reviewing two forms of identification  if 1264 
signing electronically off site. A HIPAA compliant video conferencing tool will be utilized during 1265 
the consenting process  of the telecommunication screening visit  to facilitate review of the 1266 
participant’s identification .  A copy of the informed consent  document will be given to the 1267 
participant for their records.  The rights and welfare of the participants will be protected by 1268 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 55 of 56 
 emphasizing to them that the quality of their medical care will not be adversely affected if they 1269 
decline to participate in this study. 1270 
15.3.2 Participant and Data Confidentiality 1271 
The study monitor, representatives of the IRB or device company supplying study product may 1272 
inspect all documents and records required to be maintained by the investigator, including but not 1273 
limited to, medical r ecords (office, clinic, or hospital) for the participants in this study.   1274 
The study participant’s contact information will be securely stored at the clinical site for internal 1275 
use during the study.  At the end of the study, all records will continue to be  kept in a secure 1276 
location for as long a period as dictated by local IRB and Institutional regulations. 1277 
 Participant
 1278 
The study monitor, representatives of the IRB or device company supplying study product may 1279 
inspect all documents and records required to be maintained by the investigator, including but not 1280 
limited to, medical records (office, clinic, or hospital) for the  participants in this study.   1281 
The study participant’s contact information will be securely stored at the clinical site for internal 1282 
use during the study. At the end of the study, all records will continue to be kept in a secure location 1283 
for as long a period as dictated by local IRB and Institutional regulations. 1284 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, 1285 
will be transmitted to and stored at the University of Virginia Center for Diabetes Technolo gy.  1286 
The study data entry and study management systems used by research staff will be secured and 1287 
password protected.  At the end of the study, all study databases may be de -identified and archived 1288 
at the University of Virginia Center for Diabetes Technology.  1289 
CLINICAL PROTOCOL  
 
Rocket -BPS  06-Oct-2022  Page 56 of 56 
 Chapter 16  References  1290 
1. Burdick J, Chase HP, Slover RH, et al. Missed insulin meal boluses and elevated hemoglobin 1291 
A(1c) levels in children receiving insulin pump therapy. Pediatrics. Mar 2004;113(3):E221-E224. 1292 
doi:10.1542/peds.113.3.e221 1293 
2. Cherñavvsky DR, DeBoer MD, Keith- Hynes P, et al. Use of an artificial pancreas among 1294 
adolescents for a missed snack bolus and an underestimated meal bolus. Pediatr Diabetes. Feb 1295 
2016;17(1):28-35. doi:10.1111/pedi.12230 1296 
3. Garcia -Tirado J, Brown SA, Laichuthai N, et al. Anticipation of Historical Exercise Patterns 1297 
by a Novel Artificial Pancreas System Reduces Hypoglycemia During and After Moderate - 1298 
Intensity Physical Activity in People with Type 1 Diabetes. Diabetes Technol Ther. Dec 1299 
2020;doi:10.1089/dia.2020.0516 1300 
4. Voysey, Merryn and Costa Clemens, Sue Ann and Madhi, Shabir A. et al and Group, Oxford 1301 
COVID Vaccine Trial, Single Dose Administration, And The Influence Of The Timing Of The 1302 
Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV -19 (AZD12 22) Vaccine. 1303 
Available at SSRN: https://ssrn.com/abstract=3777268 1304 